ArticleJournal of cheminformatics2026
Empowering federated learning for robust compound-protein interaction prediction across heterogeneous cross-pharma domains.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Accurately predicting novel compound-protein interactions (CPIs) is essential for accelerating drug discovery. The generalizability of machine learning-based CPI prediction models relies significantly on the availability and diversity of CPI datasets. To maximize data utility, particularly for highly confidential datasets maintained by industries, federated learning (FL)-which integrates multi-site data while preserving privacy-has emerged as a promising approach. Nonetheless, its effectiveness when applied to heterogeneous data from diverse molecular domains, a common real-world scenario, remains unclear, thereby limiting its broader adoption. This study evaluates FL for CPI prediction using datasets spanning multiple chemical and protein domains, providing practical guidance for optimizing the FL approach. Results indicate that the FL model enhanced out-of-domain prediction performance but was surpassed by local models for in-domain data under data heterogeneity. Drawing on these findings, a new strategy was developed to achieve robust performance for in- and out-of-domain tasks: a similarity-guided ensemble (SGE) that combines the global FL model with fine-tuned models based on each client's local data. This method demonstrated effectiveness with real-world industry data, including samples from the public database and 13 pharmaceutical companies. Cumulatively, these findings offer practical guidance for implementing FL in contemporary drug discovery processes. SCIENTIFIC CONTRIBUTION: This study identifies the performance trade-offs caused by heterogeneous data distributions in FL for CPI prediction. To overcome these challenges, we developed a workflow integrating local fine-tuning and a SGE, ensuring robust accuracy for both in-domain and out-of-domain predictions. The effectiveness of this approach was validated using both public datasets and real-world in-house datasets from 13 pharmaceutical companies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.